Dr. Jason M Melear
Claim this profileTexas Oncology - Austin Midtown
About Jason M Melear
Education:
- Earned an MD from the University of Texas Medical Branch at Galveston in 2009.
- Completed residency in Internal Medicine at the University of Texas Health Science Center at San Antonio in 2012.
- Finished a fellowship in Hematology/Oncology at the University of Texas MD Anderson Cancer Center in 2015.
Experience:
- Practices as a hematologist and oncologist at Texas Oncology - Austin Midtown.
- Member of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).
Area of expertise
Lymphoma
Jason M Melear has run 8 trials for Lymphoma. Some of their research focus areas include:
Cancer
Jason M Melear has run 5 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Texas Oncology-Austin Midtown
Texas Oncology, Austin
Clinical Trials Jason M Melear is currently running
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Recruiting
1 award
Phase 2
5 criteria
Tazemetostat + Lenalidomide + Rituximab
for Follicular Lymphoma
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
Recruiting
1 award
Phase 3
4 criteria
More about Jason M Melear
Clinical Trial Related
6 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Jason M Melear has experience with
- Nivolumab
- Rituximab
- Brentuximab Vedotin
- Lenalidomide
- Tazemetostat
- Doxorubicin
Breakdown of trials Jason M Melear has run
Lymphoma
Cancer
Non-Hodgkin's Lymphoma
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jason M Melear specialize in?
Jason M Melear focuses on Lymphoma and Cancer. In particular, much of their work with Lymphoma has involved metastatic patients, or patients who are Relapsed.
Is Jason M Melear currently recruiting for clinical trials?
Yes, Jason M Melear is currently recruiting for 3 clinical trials in Austin Texas. If you're interested in participating, you should apply.
Are there any treatments that Jason M Melear has studied deeply?
Yes, Jason M Melear has studied treatments such as Nivolumab, Rituximab, Brentuximab Vedotin.
What is the best way to schedule an appointment with Jason M Melear?
Apply for one of the trials that Jason M Melear is conducting.
What is the office address of Jason M Melear?
The office of Jason M Melear is located at: Texas Oncology - Austin Midtown, Austin, Texas 78731 United States. This is the address for their practice at the Texas Oncology - Austin Midtown.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.